Ketabon's Innovative Approach to At-Home Ketamine Therapy
Ketabon GmbH, a partnership between HMNC Brain Health and Develco Pharma, is gearing up to make a significant impact at the upcoming European College of Neuropsychopharmacology Congress 2024 in Milan. At this prestigious event, the company plans to unveil groundbreaking advancements in ketamine therapy, particularly for those suffering from treatment-resistant depression (TRD).
Introducing KET01: A New Hope for Patients
Ketabon's main focus will be showcasing KET01, an innovative oral prolonged-release ketamine formulation. This new treatment specifically caters to patients who haven't found relief through conventional depression medications. According to results from a Phase 2 trial of KET01, there were noteworthy improvements in depression severity, all while keeping side effects to a minimum. These findings highlight the promising potential of this new formulation.
Key Findings from Clinical Trials
The trial revealed that a daily dosage of 240mg of KET01 offers swift relief from depressive symptoms, all while maintaining a more favorable side effect profile compared to standard ketamine treatments. This is a hopeful development for individuals exploring alternative methods for managing their depression.
Highlights from the ECNP 2024 Presentation
Key executives from HMNC Brain Health and Develco Pharma, along with researchers from the University Medical Center Hamburg-Eppendorf, will be presenting two important posters during the congress. Their presentations will focus on the tolerability of KET01 and its influence on sleep quality—a concern often linked to existing methods of ketamine therapy.
Session Information
Two engaging sessions are scheduled to take place:
- Session title: PS01
Poster presentation number: P1090
Title: Acute Tolerability of Antidepressant Dose of Oral Prolonged-Release Ketamine (KET01)
Presenter: A. Damyanova and team
Track: Mental Conditions
Date & Time: Sunday, September 22, 2024, from 12:35 to 14:00 CET - Session title: PS01
Poster presentation number: P1084
Title: Evaluation of Sleep Quality During Treatment with KET01
Presenter: E. Papanastasiou and team
Track: Mental Conditions
Date & Time: Sunday, September 22, 2024, from 12:35 to 14:00 CET
KET01: A User-Friendly Treatment Option
Dr. Hans Eriksson, Chief Medical Officer of Ketabon, emphasizes the importance of these results by pointing out that KET01 enables treatment without major sleep disturbances or sedation—issues often seen with other ketamine formulations. The oral method of administering KET01 offers a unique chance for patients to manage their treatment right from home, which can greatly improve their quality of life without disrupting their daily activities.
The Future of Ketabon and Mental Health Treatments
The Ketabon initiative continues to broaden its horizons, considering the potential expansion of the oral prolonged-release ketamine formulation into other therapeutic areas. These may include anxiety, aggression, PTSD, and panic disorders. Such an expansion could significantly enhance the treatment landscape and provide additional options for patients facing these challenges.
About Ketabon GmbH and Its Partners
As a collaborative venture, Ketabon captures the innovative essence of both HMNC Brain Health and Develco Pharma. HMNC Brain Health is known for its tailored therapy approaches and ground-breaking precision psychiatry, while Develco Pharma brings expertise in advanced oral drug formulations. Together, they aim to redefine treatment methods for mental health.
Frequently Asked Questions
What is KET01?
KET01 is an oral prolonged-release ketamine formulation designed for treating treatment-resistant depression.
When will Ketabon present its findings?
Ketabon will present its findings at the ECNP Congress on September 22, 2024.
What are the outcomes of KET01's Phase 2 trial?
The Phase 2 trial showed rapid improvements in depression severity while maintaining a favorable side effect profile.
How does KET01 compare to traditional ketamine treatments?
KET01 is designed to reduce side effects like sleep disturbances and sedation, which are common with traditional ketamine therapies.
What is the mission of Ketabon?
Ketabon's goal is to develop effective at-home treatments for mental health conditions, enhancing patients' quality of life.